See also this year's filing and all EDGAR filings for this company.
PDF Report 0001730430_2022_Kiniksa_Pharmaceuticals_International_plc.pdf
Logs
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 5.279451438848921, 'aggregate_val': 38070000, 'exp_sum': -8896000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 97951000, 'ResearchAndDevelopmentExpense': 65490000, 'remainder_Expenses': -172337000}} |
Graph
Absolute values for 0001730430, Kiniksa Pharmaceuticals International plc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 196,446,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 19,250,000 |
| 2 | PropertyPlantAndEquipmentNet | 2,834,000 |
| 3 | remainder_Assets | 14,270,000 |
| 4 | LiabilitiesCurrent | 44,824,000 |
| 5 | LiabilitiesNoncurrent | 2,939,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 9,100,000 |
| 8 | SellingGeneralAndAdministrativeExpense | 288,492,995 |
| 9 | ResearchAndDevelopmentExpense | 93,174,713 |
| 10 | remainder_Expenses | 3,432,694 |
| 11 | remainder_Revenues | 38,544,000 |
| 12 | remainder_NetIncome | -18,670 |
| 13 | remainder_ComprehensiveNetIncome | -47,247 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 232,800,000 |
| 1 | Liabilities | 47,763,000 |
| 2 | Expenses | 394,200,402 |
| 3 | Revenues | 38,544,000 |
| 4 | StockholdersEquity | 185,037,000 |
| 5 | NetIncome | -355,675,072 |
| 6 | ComprehensiveNetIncome | -355,698,696 |
| 7 | BaseVar | 356,686,660 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.340 |
| 9 | EconomicCapitalRatio | 1.74 |
Edgar->Model Mapping
Feature Distribution
Change over Time
